Physician profile
Mark S Quinn
NPI 1518905470
$1,166.62
in general payments reported to CMS, 2019-2025
22 companies · $528 in 2025
The $528 reported for 2025 was more than what 75% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.79 · 2020: $31.09 · 2021: $25.01 · 2022: $79.99 · 2023: $230 · 2024: $211 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $335.53 | 2019-2025 | Calquence, Datroway, Lynparza |
| Gilead Sciences, INC. | $171.07 | 2023-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $77.97 | 2024-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $68.63 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.28 | 2019-2025 | Ninlaro |
| Stemline Therapeutics INC. | $54.64 | 2023 | Orserdu |
| Incyte Corporation | $45.77 | 2025 | Monjuvi, Zynyz |
| Janssen Biotech, INC. | $37.20 | 2023-2024 | Rybrevant, Talvey, Darzalex |
| Boston Scientific Corporation | $31.09 | 2020 | |
| Adaptive Biotechnologies Corporation | $30.99 | 2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $30.00 | 2025 | |
| Aveo Pharmaceuticals, INC. | $28.76 | 2025 | |
| Karyopharm Therapeutics INC. | $26.66 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $24.54 | 2024 | |
| Abbvie INC. | $23.25 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $20.60 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.33 | 2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $19.55 | 2023 | Libtayo |
| Tempus Ai, INC | $19.33 | 2025 | Xt Cdx |
| Coherus Oncology, INC. | $18.26 | 2024 | |
| Lilly USA, LLC | $14.33 | 2024 | Retevmo, Jaypirca, Verzenio |
| Elekta, INC. | $10.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.